A Study of RSLV-132 in Subjects With Primary Sjogren's Syndrome
Status:
Completed
Trial end date:
2019-08-01
Target enrollment:
Participant gender:
Summary
The present study will examine the role of circulating RNA complexed with autoantibodies and
immune complexes and its role in activation of inflammatory pathways in patients with primary
Sjogren's syndrome. The study will be conducted in a subset of Sjogren's patients who have
elevated levels of autoantibodies and a pattern of elevated interferon-stimulated gene
expression in blood cells. A number of biochemical and clinical parameters will be analyzed
to determine the potential therapeutic utility of nuclease therapy in Sjogren's syndrome.
Phase:
Phase 2
Details
Lead Sponsor:
Resolve Therapeutics
Collaborators:
Newcastle-upon-Tyne Hospitals NHS Trust University Hospital Birmingham